ABSTRACT
Selegiline has been one of the most controversial therapeutic agents available to treat patients with Parkinson’s disease (PD). Initially discovered in the 1960s, this drug has been suggested to have potential neuroprotective effects (1), only to be later suspected as a cause of early demise in patients with PD (2). While neither of these extreme viewpoints is widely accepted, selegiline still invokes lively discussion regarding its role as a therapeutic agent for PD. In this chapter, we will review the historical development of selegiline, its mechanism of action, short-and long-term clinical trials, and the current recommendations for its use in the management of PD.
